CytRx (CYTR) to Present Statistically Significant Evidence of Arimoclomol's Ability to Protect Experimental Animals from Effects of Hypoxia
More News related to CYTR
- CytRx Expands Management Team and Broadens Oncology Franchise
- CytRx Announces Plan to Initiate a Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Soft Tissue Sarcomas
- Pending Key Developments Ahead for CytRx Corporation (NASDAQ: CYTR)
- CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer
- CytRx Corporation (CYTR) Tops Q3 EPS by 3c
More News related to FDA
- Dyax (DYAX) Receives FDA Approval of KALBITOR(R) for Treatment of Acute Attacks of Hereditary Angioedema
- Santarus (SNTS) Earns $20 Million Milestone on FDA Approval for NDA of ZEGERID
- Santarus (SNTS) Jumps Ahead of Expected News
- Hemispherx Biopharma (HEB) Receives Letter for Ampligen From US FDA; FDA Cannot Approve Application in Present Form
- Hemispherx (HEB) Falls 30% as FDA Recommends Another Ampligen Study, Says Can't Approve Application in Present Form
CytRx Corporation (NASDAQ: CYTR) announced that an experimental animal trial produced statistically significant evidence that the company's chaperone amplifying drug candidate arimoclomol provided protection from the detrimental cognitive and sensorimotor effects of low atmospheric oxygen (hypoxia) that occurs at high altitudes. Data from this trial will be presented in a poster, "A heat-shock protein co-inducer treatment improves behavioral performance in rats exposed to hypoxia," on July 9 at the 37th Annual International Society on Oxygen Transport to Tissue (ISOTT) Conference, being held in Cleveland, Ohio.
Sign up at EasyStockAlerts for free to see your stock news before it breaks to the rest of the public!
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
